3D DOSE ESCALATION FOR PROSTATE CANCER

前列腺癌的 3D 剂量递增

• 批准号: 2100975
• 负责人: Theodore Phillips
• 金额: $ 7.48万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-06-01 至 1997-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2100975
• 关键词: cancer information system; clinical trials; computer data analysis; cooperative study; cytotoxicity; data collection; human morbidity; human subject; human therapy evaluation; male; neoplasm /cancer radiation therapy; prostate neoplasms; radiation therapy dosage; seminal vesicles

This application is in response to a request for application for studies of the use of 3-D conformal radiotherapy (3DCRT) in the definitive treatment of prostate cancer. UCSF is prepared to work with the NCI, the operations and quality assurance center and other successful applicants in designing and conducting clinical trials of 3DCRT. It is expected that initial studies will be phase I/II dose searching protocols and that after these are completed a phase III trial will be designed and carried out. The local control rate in advanced prostate cancer is relatively low and (based on recent PSA and biopsy data) patients with more limited stages have a lower local control than previously thought. It is possible that the higher doses that are possible with 3DCRT without an increase in morbidity could lead to improved cure rates. UCSF has all of the required computer hardware and an excellent 3-D treatment planning system which meets all of the requirements of the RFA. It is expected that in 1992 the UCSF group will treat 144 prostate patients with curative intent. Since 1989 the group has treated 215 prostate patients with conformal plans, 109 with a 2.5-D system and 106 with the full 3-D system. Extensive analyses have been carried out of our experience which have yielded information on the risk of nodal metastases , selection of patients for trials evaluating local control, definition of margins to be treated around the prostate and evaluation of set-up variation. We analyzed various conformal and non-conformal plans with dose volume histograms and identified a 6 field conformal technique using partial transmission blocks which compared to more conventional non-conformal techniques, allows a potential increase in dose on the order of 20%. The experience of the group in treating this number of patients with CT conformal plans, our experience in the RTOG 3DCRT committee and the studies mentioned above will assist the UCSF group in working closely under the RFA group to design optimal protocols.

本申请是回应一项研究申请的要求 三维适形放射治疗（3DCRT）在确定性 前列腺癌的治疗。 UCSF准备与NCI合作， 运营和质量保证中心及其他成功申请者 设计和进行3DCRT的临床试验。 预计 初始研究将是I/II期剂量探索方案， 在这些试验完成后，将设计并进行第三阶段试验 出去 晚期前列腺癌的局部控制率相对较低， 低水平和（基于最近的PSA和活检数据）患者， 阶段的局部控制比以前认为的要低。 是 可能的是，在没有放射治疗的情况下， 发病率增加可导致治愈率提高。 UCSF拥有所有 所需的计算机硬件和出色的三维治疗计划 满足RFA所有要求的系统。 预计 1992年，UCSF小组将治疗144名前列腺患者， 治疗意图。 自1989年以来，该组织已治疗了215名前列腺患者 109例采用2.5维系统，106例采用全三维系统 系统 对我们的经验进行了广泛的分析， 已经产生了关于淋巴结转移风险的信息， 用于评价局部控制的试验的患者， 在前列腺周围进行治疗并评估设置变化。 我们 分析了各种适形和非适形计划的剂量体积 直方图，并确定了一个6场适形技术，使用部分 与更传统的非共形传输块相比， 技术，允许剂量的潜在增加约20%。 的 治疗这么多CT患者的经验 保形计划，我们在RTOG 3DCRT委员会和 上述研究将有助于UCSF小组密切合作， 在RFA组下设计最佳方案。